Ovarian cancer

A molecularly insidious disease

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In this issue of the Chinese Journal of Cancer, European, American, and Chinese experts review the current management and future perspectives of epithelial ovarian cancer (EOC), the leading cause of gynecological cancer deaths. Although major advances have been made in understanding the cellular and molecular biology of this highly heterogeneous malignancy, the survival rate of women with EOC has changed little since the introduction of platinum-based treatment as a front-line therapy. The papers describe the progress in deciphering the molecular complexity of this disease and the newly available molecular-driven therapies, which have been applied by shifting trial designs toward restricting eligibility to specific subgroups of patients rather than testing agents in unselected populations. These new trial designs provide potential opportunities for improved efficacy in targeted populations. Given the molecular complexity of this disease, patient survival may be increased by searching for new molecular prognostic/predictive signatures as well as by translating the recent insight of microRNA involvement in EOC progression into new, targeted therapies. Particular attention has been given to the issue of fertility sparing for women affected by curable diseases.

Original languageEnglish
Pages (from-to)1-3
Number of pages3
JournalChinese Journal of Cancer
Volume34
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Ovarian Neoplasms
Neoplasms
Therapeutics
Platinum
MicroRNAs
Population
Fertility
Cell Biology
Molecular Biology
Survival Rate
Survival
Ovarian epithelial cancer

Keywords

  • Fertility preservation
  • miRNAs
  • Ovarian cancer
  • Standard of care
  • Targeted therapies

ASJC Scopus subject areas

  • Oncology

Cite this

Ovarian cancer : A molecularly insidious disease. / Mezzanzanica, Delia.

In: Chinese Journal of Cancer, Vol. 34, No. 1, 2015, p. 1-3.

Research output: Contribution to journalArticle

@article{d72481deb92246f9a5bc9422ca0d285a,
title = "Ovarian cancer: A molecularly insidious disease",
abstract = "In this issue of the Chinese Journal of Cancer, European, American, and Chinese experts review the current management and future perspectives of epithelial ovarian cancer (EOC), the leading cause of gynecological cancer deaths. Although major advances have been made in understanding the cellular and molecular biology of this highly heterogeneous malignancy, the survival rate of women with EOC has changed little since the introduction of platinum-based treatment as a front-line therapy. The papers describe the progress in deciphering the molecular complexity of this disease and the newly available molecular-driven therapies, which have been applied by shifting trial designs toward restricting eligibility to specific subgroups of patients rather than testing agents in unselected populations. These new trial designs provide potential opportunities for improved efficacy in targeted populations. Given the molecular complexity of this disease, patient survival may be increased by searching for new molecular prognostic/predictive signatures as well as by translating the recent insight of microRNA involvement in EOC progression into new, targeted therapies. Particular attention has been given to the issue of fertility sparing for women affected by curable diseases.",
keywords = "Fertility preservation, miRNAs, Ovarian cancer, Standard of care, Targeted therapies",
author = "Delia Mezzanzanica",
year = "2015",
doi = "10.5732/cjc.014.10301",
language = "English",
volume = "34",
pages = "1--3",
journal = "Chinese Journal of Cancer",
issn = "1000-467X",
publisher = "Landes Bioscience",
number = "1",

}

TY - JOUR

T1 - Ovarian cancer

T2 - A molecularly insidious disease

AU - Mezzanzanica, Delia

PY - 2015

Y1 - 2015

N2 - In this issue of the Chinese Journal of Cancer, European, American, and Chinese experts review the current management and future perspectives of epithelial ovarian cancer (EOC), the leading cause of gynecological cancer deaths. Although major advances have been made in understanding the cellular and molecular biology of this highly heterogeneous malignancy, the survival rate of women with EOC has changed little since the introduction of platinum-based treatment as a front-line therapy. The papers describe the progress in deciphering the molecular complexity of this disease and the newly available molecular-driven therapies, which have been applied by shifting trial designs toward restricting eligibility to specific subgroups of patients rather than testing agents in unselected populations. These new trial designs provide potential opportunities for improved efficacy in targeted populations. Given the molecular complexity of this disease, patient survival may be increased by searching for new molecular prognostic/predictive signatures as well as by translating the recent insight of microRNA involvement in EOC progression into new, targeted therapies. Particular attention has been given to the issue of fertility sparing for women affected by curable diseases.

AB - In this issue of the Chinese Journal of Cancer, European, American, and Chinese experts review the current management and future perspectives of epithelial ovarian cancer (EOC), the leading cause of gynecological cancer deaths. Although major advances have been made in understanding the cellular and molecular biology of this highly heterogeneous malignancy, the survival rate of women with EOC has changed little since the introduction of platinum-based treatment as a front-line therapy. The papers describe the progress in deciphering the molecular complexity of this disease and the newly available molecular-driven therapies, which have been applied by shifting trial designs toward restricting eligibility to specific subgroups of patients rather than testing agents in unselected populations. These new trial designs provide potential opportunities for improved efficacy in targeted populations. Given the molecular complexity of this disease, patient survival may be increased by searching for new molecular prognostic/predictive signatures as well as by translating the recent insight of microRNA involvement in EOC progression into new, targeted therapies. Particular attention has been given to the issue of fertility sparing for women affected by curable diseases.

KW - Fertility preservation

KW - miRNAs

KW - Ovarian cancer

KW - Standard of care

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=84920284039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920284039&partnerID=8YFLogxK

U2 - 10.5732/cjc.014.10301

DO - 10.5732/cjc.014.10301

M3 - Article

VL - 34

SP - 1

EP - 3

JO - Chinese Journal of Cancer

JF - Chinese Journal of Cancer

SN - 1000-467X

IS - 1

ER -